#acr19 @rheumnow Hench lecture: Dr Reveille HLAB15 may be a marker for peripheral arthritis in pts w/AS (OR 1.9)

Bullish on value of Polygenic Risk scores to help diagnose Axial SpA (not commercially available yet) #ACR19 @rheumnow 5T004 Reveille https://t.co/OfQYzx6yGL

VERVE results - Live zoster vaccine safe and effective in >600 patients with autoimmune diseases treated wth TNFi abstr#0824 @RheumNow #ACR19

Buyon reminds us how highly sensitive ELISA based anti-DNA assays are, caution required because more sensitive tests are often negative (crithidia/RIA) #ACR19 @RheumNow Abs 5T002 https://t.co/XN8Sfy1yHJ

2.9% of this cohort had ONSET of Inflammatory Back pain after age of 50. We don’t study this group. #ACR19 @rheumnow 5T004 Reveille https://t.co/p023BlGxPN

@SurajDhoot2 @RheumNow the speaker stated most think a tophus is just a crystal collection, but within the tophus there are a lot of biologic activity: cytokines, fibroblasts, macrophages.... driven by the crystals. The treatment is the same (ULT)but it might also explain why IL-1 inh helps inflmm

#acr19 @rheumnow Hench Lecture w/Dr J Reveille on back pain to HLA B27 20% of people 20-50 yrs old in US have chronic back pain. How many of you have back pain now?

Important point that we must adjust for duration of treatment when looking at irAEs as a biomatker for tumor response to ICI- even when you do, however, any grade irAE is associated with better outcome! #ACR19 @LCalabreseDO @CCalabreseDO @drdavidliew

@cappelliMD @LCalabreseDO @CCalabreseDO Jeffrey Weber today at #ACR19: "I'm a T cell chauvinist... turns out that B cells are extraordinarily important in the onset of irAEs." Autoantibodies important in irAEs - Jeffrey Weber's convinced! shout out to @jessbq @ONJ_TILs

PMR treatment with no oral steroids, low dose MTX and occasional steroid injections? Surprising and intriguing: little success previously in non-steroid paradigm in PMR, more data on this please, def worth further testing! Hospital 12 de Octubre, Madrid #ACR19 ABST0742 @RheumNow https://t.co/I15GA4gjPw

Takayasu's arteritis isn't just one, homogenous disease - and different phenotypes have different outcomes. Interesting from @petercgrayson's group at @NIH_NIAMS #ACR19 ABST0753 @RheumNow https://t.co/sWxUGaCRq2

You heard it from the oncologist- autoimmune disease is NOT an exclusion criterion for being treated with immune checkpoint inhibitors! Flare is common but manageable #ACR19

Here are the results of the poll. Thanks for participating. We look forward to more studies that will help us answer this important question 🤫 #ACR19 @RheumNow https://t.co/q3AJZS6spj

• Dr. Antoni Chan on Twitter: "Does anti-TNF treatment halt radiographc prog…

GiACTA What happened when weekly TCZ stopped? 42% maintained clinical remission on NO treatment at end 2yr Part2 What happened when Pred stopped (this happened in part1)? Taper 26wk: 32% no flare over yr Taper 52wk: 51% no flare over that yr #ACR19 @rheumnow Abst0808

GiACTA 1: blinded injections stopped wk52 Part 2: 2yrs Time to flare after remission Most flares in part 1 in those randomised to GC alone Lowest cumulative GC doses over 3y in TCZ-QW (50% less) #ACR19 @rheumnow Abst0808